Detalhe da pesquisa
1.
Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and meta-analysis.
Clin Endocrinol (Oxf)
; 97(5): 519-531, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261059
2.
Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.
Neuroendocrinology
; 109(1): 7-19, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30889571
3.
Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
Neuroendocrinology
; 104(3): 273-279, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27161443
4.
Acromegaly: clinical features at diagnosis.
Pituitary
; 20(1): 22-32, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27812777
5.
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.
Pituitary
; 19(4): 448-57, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27279011
6.
Medical combination therapies in Cushing's disease.
Pituitary
; 18(2): 253-62, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25647330
7.
Multiple facets in the control of acromegaly.
Pituitary
; 17 Suppl 1: S11-7, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24272033
8.
"Micromegaly": Acromegaly with apparently normal GH, an entity on its own?
Best Pract Res Clin Endocrinol Metab
; 38(3): 101878, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519400
9.
Accuracy of the 10 µg desmopressin test for differential diagnosis of Cushing syndrome: a systematic review and meta-analysis.
Front Endocrinol (Lausanne)
; 15: 1332120, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38352712
10.
Thyroid cancer in patients with acromegaly: a case-control study.
Pituitary
; 16(1): 109-14, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22527615
11.
Subclinical Ventricular Dysfunction in Long-Term Acromegaly Assessed by Speckle-Tracking Echocardiography.
Front Endocrinol (Lausanne)
; 13: 812964, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35185796
12.
Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Endocrine
; 76(3): 642-647, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35237910
13.
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Pituitary
; 14(2): 148-56, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21104199
14.
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638340
15.
Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism.
Arch Endocrinol Metab
; 65(2): 212-230, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33905631
16.
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
J Clin Endocrinol Metab
; 106(7): 2047-2056, 2021 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686418
17.
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Pituitary
; 13(2): 123-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19943118
18.
Management of prolactinomas in Brazil: an electronic survey.
Pituitary
; 13(3): 199-206, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20107911
19.
Relationship between Prolactin, Chronic Kidney Disease, and Cardiovascular Risk.
Int J Endocrinol
; 2020: 9524839, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32655635
20.
Brazilian multicenter study on pegvisomant treatment in acromegaly.
Arch Endocrinol Metab
; 63(4): 328-336, 2019 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365632